Download Neuroblastoma Ebook PDF

Neuroblastoma

Neuroblastoma
Clinical and Surgical Management

by Sabine Sarnacki,Luca Pio

  • Publisher : Springer
  • Release : 2019-08-12
  • Pages : 383
  • ISBN : 3030183963
  • Language : En, Es, Fr & De
GET BOOK

This book addresses neuroblastoma, a type of embryonic tumor derived from neural crest cells and one of the most frequent extra-cranial solid tumors in children. However, the term also describes a heterogeneous group of tumors, the prognosis of which can differ greatly according to age, stage and biology. Some forms undergo spontaneous regression, and some are cured by surgery alone or after chemo-reduction, while others exhibit extremely aggressive behavior. Their successful treatment is one of the best examples of tailored medicine, which involves close collaboration between pediatric surgeons, pediatric oncologists, radiologists, nuclear medicine specialists, biologists, oncogeneticists and radiotherapists. The book pursues a unique approach, as it combines most essential insights from all of these fields, together with key information regarding epidemiology, physiopathology and palliative care. The respective chapters were written by the leading international experts on neuroblastoma, and present the latest advances in terms of research, surgical approaches and medical treatments. The book offers an invaluable resource to all pediatric surgeons, pediatricians, oncologists, students, researchers and all others involved in neuroblastoma management who want to benefit from their colleagues’ expertise.

Neuroblastoma

Neuroblastoma
Current State and Recent Updates

by Chandrika Gowda

  • Publisher : BoD – Books on Demand
  • Release : 2017-10-25
  • Pages : 168
  • ISBN : 953513583X
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-risk patients receive multimodality treatment, including chemotherapy, surgery, radiation therapy, biologic therapy and immunotherapy, all of which are associated with significant morbidity. Recent years have seen many advances in treatment of neuroblastoma, including therapeutic MIBG, immunotherapy, and personalized targeted therapy based on the genetic alterations seen in the tumor. The primary objective of this book is to provide the readers with a comprehensive review of neuroblastoma, from clinical aspects and the currently available treatment to recent advancements and future directions in the field of NBL treatment. The topics and chapters have been compiled keeping in mind a diverse group of readers in different areas of specialty such as pediatric oncology, surgery, radiation oncology, and immunology, as well as physician scientists and basic researchers working in the field of neuroblastoma.

The Neurology of Neuroblastoma

The Neurology of Neuroblastoma
Neuroblastoma as a Neurobiological Disease

by Nina Felice Schor

  • Publisher : Springer Science & Business Media
  • Release : 2012-12-06
  • Pages : 90
  • ISBN : 1461510570
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is the single most common solid tumor of childhood. Although children with small primary neuroblastomas alone are almost always cured by surgery, 65% of children with neuroblastoma already have large bulky tumors or metastatic disease by the time of initial diagnosis. For these children, the 5-year survival rate is only somewhere between 5% and 20% with therapies including surgery, radiation, chemotherapy, and bone marrow transplantation. Dr Schor outlines a new approach to these tumors in order to make a difference for these children. There is much information to support the notion that neuroblastomas represent a developmental aberration of the nervous system, rather than a de novo abnormality in a previously normal cell. While the remote, paraneoplastic effects of neuroblastoma are often the purview of the child neurologist, the neoplasm itself has been viewed and approached therapeutically in much the same manner as all other solid tumors, as the purview of the pediatric oncologist. This work takes the view that approaching neuroblastoma rather as a disorder of nervous system development offers new therapeutic possibilities for this common tumor of childhood.

Neuroblastoma

Neuroblastoma
A Book

by Nai-Kong V. Cheung,Susan L. Cohn

  • Publisher : Springer Science & Business Media
  • Release : 2006-03-30
  • Pages : 300
  • ISBN : 354026616X
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is a medical enigma. As a childhood neoplasm arising from neural crest cells, it is characterized by diverse clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. Although clinical outcome can be predicted to a large extent by the stage of disease and the age at diagnosis, an in-depth understanding of its clinico-pathological behavior, now greatly aided by sophisticated molecular genetic profiling, will improve diagnostic precision and refine risk-based therapies. Comprehensive international efforts have advanced our understanding of tumor biology and improved the clinical management of children with neuroblastoma. This book reviews our current understanding of the genes and biological pathways that contribute to neuroblastoma pathogenesis, modern risk-based treatment approaches for these patients, and recent advances in biologically based therapy. It provides a concise up-to-date reference for practitioners, students, and researchers.

Neuroblastoma

Neuroblastoma
A Book

by Carl Pochedly

  • Publisher : Unknown Publisher
  • Release : 1976
  • Pages : 314
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma

Neuroblastoma
A Book

by Carl E. Pochedly

  • Publisher : CRC Press
  • Release : 1990-06-21
  • Pages : 424
  • ISBN : 9780849301575
  • Language : En, Es, Fr & De
GET BOOK

The purpose of this book is to provide a comprehensive review of current knowledge and to give a thoughtful assessment of the many complex issues involved in the diagnosis and treatment of this common malignant solid tumor found in children. This up-to-date publication also reviews new concepts in histogenesis and histopathology of neuroblastoma. Divided into three main sections, this work focuses on tumor biology, clinical management, and prognosis and future perspectives. This fascinating work includes in-depth discussions on neuroblastoma in infancy and the manifestations of this tumor as it affects various organs and various parts of the body. It also provides guidelines for treatment with surgery, radiotherapy and chemotherapy. This ideal resource is loaded with information for all those who care for children with cancer, including pediatric oncologists, medical oncologists, pathologists, radiotherapists, pediatric nurse oncologists and pediatricians.

Neuroblastoma

Neuroblastoma
MIBG in Its Diagnosis and Management

by Judy Moyes,V. R. McCready,Ann Fullbrook

  • Publisher : Springer Verlag
  • Release : 1989
  • Pages : 168
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Cancer Genomics

Cancer Genomics
Chapter 21. Neuroblastoma

by Daniel A. Morgenstern,Meredith S. Irwin

  • Publisher : Elsevier Inc. Chapters
  • Release : 2013-11-21
  • Pages : 510
  • ISBN : 0128061189
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is one of the most common childhood tumors and has a remarkably diverse pattern of presentation and clinical behavior. Current management approaches rely on risk stratification using clinical, pathological and, increasingly, genetic factors. This chapter explores the current state of knowledge of the genetic factors behind neuroblastoma and discusses how these may impact on treatment. Both segmental chromosomal abnormalities (including loss of 1p or 11q, or gain of 17q) and changes in individual genes (such as MYCN amplification, mutations in ALK and ATRX) have been implicated in neuroblastoma pathogenesis. Recent whole-genome approaches have identified multiple genetic variants (involving LMO1, BARD1, LIN28B, NBPF23 and others) that may predispose to neuroblastoma, while germline mutations in ALK and PHOX2B are associated with rare familial cases of neuroblastoma. The roles of mRNA gene expression profiling, microRNAs that regulate protein translation from mRNA and epigenetic modifications (such as DNA methylation) in neuroblastoma are also discussed. Incorporation of subsets of these genomic factors into risk stratification will ultimately lead to more personalized treatment for neuroblastoma patients.

Progressive Neuroblastoma

Progressive Neuroblastoma
Innovation and Novel Therapeutic Strategies

by H. Christiansen,N.M. Christiansen

  • Publisher : Karger Medical and Scientific Publishers
  • Release : 2015-09-28
  • Pages : 192
  • ISBN : 3318054976
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is a tumor derived from the sympathetic nervous system. It is the most common extracranial solid tumor occurring in children and exhibits a marked variability in outcome when the disease is categorized by clinical (e.g. age or stage) and biologic characteristics. This book gives an introduction into the clinical features of progressive neuroblastoma and focuses on molecular-targeted therapies and immunotherapies of this disease. It has become increasingly clear that MYCN (v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog) holds a key position in neuroblastic transformation and gene expression in normal and transformed cells. In the 14 chapters important topics such as genomic alterations in neuroblastoma and strategies for indirect molecular targeting of MYCN are discussed. Two chapters, for example, review apoptotic pathways and proapoptotic molecular targets in neuroblastoma, one focusing on the p53 pathway and the extrinsic and intrinsic pathways of apoptosis. Other chapters cover topics related to immunology in neuroblastoma, such as immune regulation in neuroblastoma, immunotherapy related to passive and active vaccination approaches and additional immunotherapy in the treatment of progressive disease. This volume will be essential reading for all clinicians and basic researchers who are involved in delivering health care to patients with progressive neuroblastoma.

Neuroblastoma

Neuroblastoma
Molecular Mechanisms and Therapeutic Interventions

by Swapan K. Ray

  • Publisher : Academic Press
  • Release : 2019-01-11
  • Pages : 334
  • ISBN : 0128120045
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma: Molecular Mechanisms and Therapeutic Interventions comprehensively reviews current concepts in molecular and histopathological mechanisms that influence the growth of human malignant neuroblastoma, along with exciting therapeutic interventions. This book features a broad collection of contributions from leading investigators in histopathology, molecular mechanisms, genetics, epigenetics, microRNAs, proteomics, and metabolism in controlling growth and death in neuroblastoma. Recent developments in therapeutic interventions for neuroblastoma are also covered extensively, including chapters on surgery, chemotherapy, targeted therapy and immunotherapy. This book is ideal for advanced undergraduate students, graduate students, medical students, postdoctoral fellows, and investigators with an interest in current molecular concepts and therapeutic interventions. Comprehensively covers the histopathological characterization, molecular mechanisms, and most recent therapeutic interventions in neuroblastoma Includes recent developments and therapeutic interventions for neuroblastoma, including chapters on surgery, chemotherapy, targeted therapy and immunotherapy Presents a broad scope that provides basic researchers, practitioners and students with the most current overview of recent advances

Neuroblastoma

Neuroblastoma
Present and Future

by Hiroyuki Shimada

  • Publisher : BoD – Books on Demand
  • Release : 2012-02-08
  • Pages : 378
  • ISBN : 9533070161
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma, once called "enigmatic", due to "unpredictable" clinical behaviors, is composed of biologically diverse tumors. Molecular/genomic properties unique to the individual tumors closely link to the clinical outcomes of patients. Establishing risk stratification models after analyzing biologic characteristics of each case has made a great success in patient management. However, the trend of improving survival rates in neuroblastoma over the last 30 years has started to level off, and currently available treatment modalities have almost reached to their maximized intensity. Furthermore, aggressive treatment causes significant long-term morbidities to the survivors. We really need to make the next step to the level of personalized medicine with more precise understanding of neuroblastoma biology. This book includes useful data and insights from the world's experts in this field. I believe this book can make an excellent contribution to all the investigators working hard and fighting for the children stricken by this disease.

Focus on Neuroblastoma Research

Focus on Neuroblastoma Research
A Book

by Julio A. Fernandes

  • Publisher : Nova Publishers
  • Release : 2007
  • Pages : 212
  • ISBN : 9781600214844
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is a cancer that develops from nerve cells found in several areas of the body. Neuroblastoma most commonly affects children age 5 or younger, though it may rarely occur in older children and adults. Neuroblastoma is the most common cancer in babies. Neuroblastoma develops in tissue that makes up the sympathetic nervous system -- the system of nerves that automatically regulates your heart rate, blood pressure and digestion. Neuroblastoma most commonly arises in and around the adrenal glands, which sit atop the kidneys. However, Neuroblastoma can also develop in other areas of the abdomen and in the chest, neck and pelvis. This book presents important research in this field of research.

Pathophysiology of Neuroblastoma

Pathophysiology of Neuroblastoma
A Book

by Patrick Kimuyu

  • Publisher : GRIN Verlag
  • Release : 2018-01-29
  • Pages : 7
  • ISBN : 3668624429
  • Language : En, Es, Fr & De
GET BOOK

Document from the year 2018 in the subject Medicine - Epidemiology, grade: 1, Egerton University, language: English, abstract: Neuroblastoma refers to a malignant cancer disease that affects the nerve tissue in different parts of the body, primarily the nerve tissue of the spinal cord, adrenal glands, chest and neck. However, the disease is believed to begin from the adrenal glands and spread to the other nerve tissues. In most cases, neuroblastoma sets in the early childhood, especially in children below the age of 5 years, and persists into adulthood. In rare occasions, malignant cancer cells form during the fetal development stages of the fetus, long before the child is born, as it has been identified in ultrasound results. In practice, neuroblastoma presents some difficulties in both management and diagnosis because this cancer spreads rapidly and this explains why diagnosis is usually done when the disease has already metastasized to the bones, lymph nodes, skin and the liver.

The Neurology of Neuroblastoma

The Neurology of Neuroblastoma
Neuroblastoma As a Neurobiological Disease

by Nina Felice Schor

  • Publisher : Springer Science & Business Media
  • Release : 2002-08-31
  • Pages : 90
  • ISBN : 9781402071447
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is the single most common solid tumor of childhood. Although children with small primary neuroblastomas alone are almost always cured by surgery, 65% of children with neuroblastoma already have large bulky tumors or metastatic disease by the time of initial diagnosis. For these children, the 5-year survival rate is only somewhere between 5% and 20% with therapies including surgery, radiation, chemotherapy, and bone marrow transplantation. Dr Schor outlines a new approach to these tumors in order to make a difference for these children. There is much information to support the notion that neuroblastomas represent a developmental aberration of the nervous system, rather than a de novo abnormality in a previously normal cell. While the remote, paraneoplastic effects of neuroblastoma are often the purview of the child neurologist, the neoplasm itself has been viewed and approached therapeutically in much the same manner as all other solid tumors, as the purview of the pediatric oncologist. This work takes the view that approaching neuroblastoma rather as a disorder of nervous system development offers new therapeutic possibilities for this common tumor of childhood.

Pheochromocytoma, Paraganglioma and Neuroblastoma

Pheochromocytoma, Paraganglioma and Neuroblastoma
A Book

by Pasquale Cianci,Enrico Restini,Amit Agrawal

  • Publisher : BoD – Books on Demand
  • Release : 2021-08-18
  • Pages : 130
  • ISBN : 1839689471
  • Language : En, Es, Fr & De
GET BOOK

Pheochromocytoma, paraganglioma and neuroblastoma are the most common neural crest-derived tumors in adults and children, respectively. These neoplasms are associated with significant morbidity and mortality. Some international studies currently underway are researching and evaluating the presence of any similarities and differences between these tumors. Hopefully, future results will reveal several potential novel genes and pathways that might have major roles in the pathogenesis and progression of these neoplasms. This book discusses epidemiology, genetics, and treatment of these malignancies.

MicroRNA-506-3p as a Differentiation Agent for Neuroblastoma

MicroRNA-506-3p as a Differentiation Agent for Neuroblastoma
A Book

by Michaela Marie Sousares

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 142
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Neuroblastoma is the most common solid tumor cancer in infants less than 1 year of age, and the second most common extracranial cancer in children. Approximately 60% of the cases have already spread to the lymph nodes at diagnosis, where children with this disease typically do not live past 10 years of age. The high mortality rate of this cancer arises from the failure of neural crest cell precursors to differentiate, which inhibits the maturation of these cells, leaving immortal, infant malignancies. 13-cis-retionoic acid is currently used as the agent of choice for neuroblastoma, but exhibits a 50% recurrence of tumor cells, leaving the identification of new targets a crucial step in the elucidation of neuroblastoma. MicroRNAs are small, noncoding RNAs, that regulate transcription and the expression of many genes. They perform posttranscriptional gene modification by translational suppression, mRNA degradation, or site-specific cleavage of mRNAs. The dysregulation of these molecules leads to tumor development and metastasis, along with chemoresistance and multidrug resistance. MicroRNA mimics are partially double-stranded RNAs designed to mimic the function of endogenous miRNAs, effectively increasing the level of cellular miRNAs. Recent studies have provided evidence for the use of miRNAs in the induction of differentiation of neuroblastoma cells, which induce malignant cells to mature and undergo apoptosis. More recently, a novel miRNA, miR-506-3p, was identified as a potent inducer of neuroblastoma cell differentiation by the down-regulation of two target genes at the 3'UTR target site, suggesting this as an effective differentiation agent for neuroblastomal remission therapy. The current study examined the effects of retinoic acid and miR-506-3p mimic, alone and in combination, on undifferentiated neuroblastoma cells. To approach this, techniques such as cell culture, forward and reverse transfection, neurite outgrowth assays, cell viability assays, cell proliferation assays, and Western Blot were used to quantify the differentiation-inducing effect of these treatments. For both all-trans-retinoic acid (ATRA) and microRNA-506-3p mimic-treated cells with different genetic backgrounds, there were variations in the responses. More cell lines responded to the miR-506-3p mimic, indicating the possibility of a more generic effect than ATRA on neuroblastoma cell differentiation. For combined treatments, all experimental values were less than predicted. In sum, the results provided here support the hypothesis that the miR-506-3p mimic may have a more generic effect than ATRA on neuroblastoma cell differentiation, but we cannot report synergism for the response following combined treatments on neuroblastoma cell viability.

Tumor Suppressive Functions of Krüppel-Like Factor 4 (Klf 4) in Neuroblastoma

Tumor Suppressive Functions of Krüppel-Like Factor 4 (Klf 4) in Neuroblastoma
A Book

by Lai-Shan Tsoi,蔡麗珊

  • Publisher : Open Dissertation Press
  • Release : 2017-01-27
  • Pages : 129
  • ISBN : 9781361368176
  • Language : En, Es, Fr & De
GET BOOK

This dissertation, "Tumor Suppressive Functions of Krüppel-like Factor 4 (KLF 4) in Neuroblastoma" by Lai-shan, Tsoi, 蔡麗珊, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Neuroblastoma is a childhood solid tumor of a unique propensity to either regress spontaneously or grow relentlessly. Emerging evidence indicated that neuroblastoma contains heterogeneous populations of cells, and commitment of these cells to neuronal lineage may result in aggressive progression in patients, whereas to fibromuscular lineage may give a favorable outcome. However, mechanism(s) controlling the lineage commitment of neuroblastoma cells remains to be identified. Our preliminary data suggested that Kr?ppel-Like Factor 4 (KLF4) might promote neuroblastoma regression. KLF4 is a transcription factor regulating a variety of cellular functions, including proliferation and cell cycle progression. Recent studies have demonstrated that KLF4 may act as both tumor suppressor and oncogene in a cell-context dependent manner. Importantly, our preliminary data showed that low KLF4 expression is highly associated with poor clinical outcomes of the neuroblastoma patients. In addition, we found that overexpression of KLF4 suppresses neuroblastoma cell growth accompanied with loss of tumorigenicity. Morphologically, KLF4 overexpressing cells changed their morphologies to become epithelial-like, strongly substrate-adherent and expressing smooth muscle marker. Therefore, we hypothesized that KLF4 exerts its effects through two ways, it may (i) function to inhibit cell growth and reduce tumorigenicity; and (ii) promote differentiation of the neuroblastoma cells to the non-tumorigenic, fibromuscular-like cells. RT-PCR data revealed the differential expression of KLF4 in 11 neuroblastoma cell lines. In particular, a modest expression was found in Be(2)C, a cell line which was formerly demonstrated to differentiate and form tumor in mice xenograft assay. It was therefore chosen as the study model. To assess the effects of KLF4 knockdown on tumor growth, stable knockdown clones from Be(2)C cells were established by lentiviral transduction of KLF4-targeting shRNA. In parallel, clones that stably expressed non-target shRNA were used as controls. After the transduction, two stable knockdown clones showing significant KLF4 downregulation were isolated from single colony (monoclonal stable clones) and a pool of cells (polyclonal stable clones) respectively. The cell proliferation and growth rate of the stable clones were then measured by 5-bromo-2'-deoxyuridine (BrdU) proliferation assay and growth curve assay. The results have indicated that both monoclonal and polyclonal stable KLF4 knockdown clones grow faster than the control clones. In order to examine the tumorigenicity in vivo, the stable clones were xenotransplanted to severe combined immunodeficient mice. The stable KLF4 knockdown clones showed a significant higher growth rate and formed a larger tumor. The stable clones were also treated with BrdU for four weeks for differentiation towards fibromuscular lineage. As anticipated, the control clones showed fibromuscular features, like more flattened and epithelial-like morphology. In contrast, the stable KLF4 knockdown clones failed to present the fibromuscular features after treatment. In addition,

Neuroblastoma

Neuroblastoma
Clinical and Biological Manifestations

by Carl Pochedly

  • Publisher : North-Holland
  • Release : 1982
  • Pages : 315
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

The Use of Both Diagnostic and Therapeutic MIBG in Neuroblastoma Patients

The Use of Both Diagnostic and Therapeutic MIBG in Neuroblastoma Patients
A Book

by Gitta Bleeker

  • Publisher : Unknown Publisher
  • Release : 2014
  • Pages : 328
  • ISBN : 9789090282176
  • Language : En, Es, Fr & De
GET BOOK

Metastasis and Angiogenesis in Neuroblastoma

Metastasis and Angiogenesis in Neuroblastoma
Involvement of Visinin Like Protein-1 and Dendritic Cell

by Yi Xie

  • Publisher : Unknown Publisher
  • Release : 2017-01-27
  • Pages : 129
  • ISBN : 9781374673472
  • Language : En, Es, Fr & De
GET BOOK

This dissertation, "Metastasis and Angiogenesis in Neuroblastoma: Involvement of Visinin Like Protein-1 and Dendritic Cell" by Yi, Xie, 謝弋, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Abstract of thesis entitled Metastasis and Angiogenesis in Neuroblastoma: Involvement of Visinin Like Protein-1 and Dendritic Cell Submitted by Xie Yi (谢弋) For the degree of Doctor of Philosophy at the University of Hong Kong in January 2007 In the present study, I have demonstrated that metastasis of neuroblastoma is linked intimately with the proliferative and invasive phenotypes of tumor cells. Using invasion trans-well assays, two sub-populations of cells representing highly invasive cells (HI cells) and low invasive cells (LI cells) were isolated from human neuroblastoma cell line SK-N-AS. Subsequently, it was shown that HI cells displayed higher metastatic property but lower proliferative rate than LI cells in culture and in nude mice. In addition, they displayed distinct sensitivities to chemotherapy drugs, and HI cells were more sensitive to Etoposide (VP-16) and Adriamycin than LI cells. Affymetrix microarray analysis and quantitative RT-PCR revealed elevated Visinin Like Protein-1 (VSNL-1) mRNA in HI cells as compared to LI cells. Over-expression of VSNL-1 in LI cells resulted in reduction of cell proliferation but enhanced invasion ability. Furthermore, modified LI cells over-expressing VSNL-1 produced frequent distant metastasis in nude mice as compared to the original un-modified LI cells. Upregulation of VSNL-1 potentiated the anoikis-resistant ability of neuroblastoma cell, concomitant with the upregulation of anoikis inhibitor TrkB, down-regulation of intracellular adhesion molecule 1 (ICAM-1), major histocompatibility complex class I (MHC-1), CD44 and CD44v6. In line with the ability of VSNL-1 to enhance metastasis of neuroblastoma cells, VSNL-1 was highly expressed in tumor specimens from patients with distant metastasis as compared to those without metastasis. The level of VSNL-1 mRNA in Stage 4 patients was over 13 times higher than that in Stage 1 patients. Taken together all these data revealed distinctive roles of proliferative and invasive phenotypes of neuroblastoma cells in tumor progression, and strongly indicated that VSNL-1 played a very important role in neuroblastoma metastasis. Vascular endothelial growth factor (VEGF)-mediated angiogenesis plays very important roles in tumor growth and metastasis, not only because of VEGF-induced angiogenesis, but also due to VEGF-related immunosuppression. It has been recently reported that dendritic cells (DCs) infiltration and VEGF expression are inversely correlated in tumor specimens. It was also observed that the plasma levels of VEGF in tumor patients decreased during DC-based immunotherapy, but the underlying mechanism remains unclear. The current report is the first study to demonstrate that DCs are able to inhibit tumor angiogenesis by internalizing and clearance of VEGF via VEGF receptor-1 (Flt-1). Furthermore, our in vivo data showed that administration of DCs alone into neuroblastoma-bearing nude mice could significantly decrease the serum VEGF levels and inhibited tumor growth. The role of DC on clearance of VEGF highlights a novel function of DC in anti-tumor therapy, 2through the inhibition of tumor angiogenesis. Current findings have therefore provided a new basis for the DC-based anti-tumor therapeutic strategy, not only because it promotes anti-tumor immunity but also for its anti-angiogenic potential. (Word count: 445) 3 DOI: 10.5353/th_b385882